Spigelman Melvin K 4

What Happened

• Melvin K. Spigelman, a director of AN2 Therapeutics, was granted a derivative award on Feb 20, 2026 covering 20,400 shares. The award shows an acquisition price of $0.00 (no cash paid at grant) and is reported as a derivative security (an option/award rather than an immediate stock purchase). This is an award grant, not a sale — typically a routine equity incentive for service.

Key Details

• Transaction date: 2026-02-20; Form filed: 2026-02-23 (timely filing).
• Security: derivative award covering 20,400 shares; acquisition price reported $0.00.
• Vesting: per footnote, the option shares shall vest on Feb 20, 2027, subject to continuous service through that date.
• Shares owned after the transaction: not specified in the provided excerpt of the filing.
• Transaction code: A (award/grant/other acquisition); not a 10b5-1 trade, sale, or tax withholding event.

Context

• This is a typical equity incentive (grant of options/awards) granted to a director and does not reflect an immediate purchase or sale of stock. The economic value is realized only if and when the options vest (Feb 20, 2027) and are exercised according to the award terms. Such grants are common for aligning director incentives with shareholder interests.